Galderma agrees to buy ZO Skin Health and Galderma stock costs EUR 179.60

Published on 10/14/2026 at 10:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ZO Skin Health spans 40 countries and more than 16,500 accounts globally. Galderma stock costs EUR 179.60 on October 14, 2026 in trading.

Acquisition expands skincare portfolio

Galderma agreed to acquire ZO Skin Health for USD 1.50 billion on October 14, 2026.
First-half 2026 net sales increased 24.60 percent at constant currency.
Galderma stock was trading at EUR 179.60 at 10:11 a.m. CEST on October 14, 2026 at Lang & Schwarz.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 179.60 at Lang & Schwarz on October 14, 2026 at 10:11 a.m. CEST as Galderma agreed to acquire ZO Skin Health for USD 1.50 billion. Galderma said on October 14, 2026, that the transaction should be Core EPS neutral in the first full year after closing.

Three events shape the story

On September 21, 2026, Galderma entered the Swiss Market Index, while first-half 2026 net sales increased 24.60 percent at constant currency. The company raised its full-year 2026 net sales growth guidance to 19.00-21.00 percent from 17.00-20.00 percent, according to Business Wire.

On October 8, 2026, Galderma presented three-year Nemluvio data. Among early responders in the ARCADIA long-term extension study, 76.00 percent achieved clear or almost clear skin at Week 152, while 80.00 percent achieved at least a 90.00 percent improvement in disease severity, Galderma reported.

What does the purchase change?

ZO Skin Health adds more than 40 products and a network of more than 16,500 physician, medical spa and online accounts across more than 40 countries. The brand recorded net sales of USD 330.00 million in the twelve months through June 2026, giving Galderma a sizeable addition to its dermatological skincare portfolio.

The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions. Galderma said the deal should slightly dilute its Core EBITDA margin in 2027 before reaching a margin broadly comparable with the group average from 2028.

Growth meets integration costs

The acquisition extends Galderma's existing skincare platform, which includes Cetaphil and Alastin, but the planned commercial investment creates a near-term execution issue. The company expects Core EPS neutrality only in the first full year after closing, while the margin effect is expected to remain slightly negative in 2027.

Transaction timing stays open

The announced closing window runs from the fourth quarter of 2026 into early 2027. That timetable leaves regulatory clearance and integration spending as the immediate milestones for the acquisition thesis.

Stock trades during the Swiss session

Galderma stock was trading at EUR 179.60 at Lang & Schwarz on October 14, 2026 at 10:11 a.m. CEST. The primary listing is on SIX under ticker GALD, and the stock's 52-week range was CHF 134.70 to CHF 188.25 as of October 14, 2026.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.